CLL-769: Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): Post Hoc Analyses From the SEQUOIA Study
Mazyar Shadman(University of Washington), Talha Munir(Leeds Teaching Hospitals NHS Trust), Danielle M. Brander(Duke University), Nataliya Kuptsova‐Clarkson, Jamie Hirata(Universidad San Carlos), Marcus Lefebure(Peter MacCallum Cancer Centre), Tian Tian, Stephanie Agresti, Constantine S. Tam(The Alfred Hospital)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453